Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin delta - Ferring Pharmaceuticals

Drug Profile

Follitropin delta - Ferring Pharmaceuticals

Alternative Names: FE-999049; Recombinant follicle-stimulating hormone - Ferring Pharmaceuticals; Recombinant FSH - Ferring; Rekovelle

Latest Information Update: 16 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 16 Dec 2019 Ferring Pharmaceuticals completes a phase I trial for Female infertility (In volunteers) in China (SC, Injection) (NCT04150861)
  • 08 Jul 2019 Ferring Pharmaceuticals completes a phase III trial in Female infertility in Japan (SC) (NCT03228680)
  • 23 Jun 2019 Ferring Pharmaceuticals initiates a phase I trial for Female infertility (In volunteers) in China (SC, Injection) (NCT04150861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top